Futurama: Psychedelics w/ Sher Ali Butt of CB Therapeutics

Topics:Starting the first private company that could biosynthesize psilocybin in yeastIntroducing psychedelics and some of the science behind it.The challenges of raising funds for a cannabis company and what changed.How YC was able to add value for BioTech company.Why big pharma is not moving into the psychedelic space.What the biggest challenge in the psychedelics market today.Where psychedelics will be in 2030Sher Ali Butt is the co-founder and CEO of CB Therapeutics, a company focused on producing high-value molecules, compounds, and rare ingredients from simple feedstock. CB Therapeutics' experience in synthetic genomics, bio-engineering, and cellular production processes have made them the first company in the world to produce (and file IP for) natural tryptamines and their analogs, in yeast. This process allows them to produce a broad range of compounds efficiently, sustainably, faster, at greater yields, and with higher purity and consistency than any other competitive platforms. Sher was formerly the co-founder and CSO of a Laboratory testing firm and has worked for a number of leading pharmaceutical and wellness product companies. Sher has a B.S. in Biochemistry & Molecular Biology from UC Davis and an MBA from the Rady School of Management, UC San Diego. As of today, CB Therapeutics' team consists out of 19 employees, including 7 doctorate degree (PhD) holders and 9 research associates. This team has advanced our proprietary yeasts formulation and production processes to become the market leader in the development of novel molecules.Read the Futurama here: https://venturebrief.substack.com/p/1-futurama-psychedelicsLinkedin: https://www.linkedin.com/in/sherbutt/Twitter: https://twitter.com/cbthera?lang=enWebsite: https://www.cbthera.com/